Lymphoma, Non-Hodgkin: all 2,043 studies
Page 13 of 21. Open to participants first (309), then studies with results posted, then the rest; newest registration first within each.
- Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's LymphomaStatus unknownNCT03456466Phase 1/2
- Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell LymphomaCompletedNCT03450343Phase 1
- Vinorelbine for Recurrent ALCL-2017CompletedNCT03443128Phase 2
- AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin LymphomaActive, not recruitingNCT03434769Phase 1
- Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast CancerTerminatedNCT03432741Phase 1
- Safety, Tolerability, PK/PD of FE 203799 in Adults With LymphomasWithdrawnNCT03417765Phase 1/2
- TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin LymphomasCompletedNCT03410901Phase 1
- Vinorelbine for Recurrent ACLCCompletedNCT03397953Phase 2
- Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's LymphomaTerminatedNCT03379493Phase 1
- Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell LymphomasWithdrawnNCT03373305Phase 1
- Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)Status unknownNCT03373019Phase 2
- A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin LymphomaWithdrawnNCT03369964Phase 1
- Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma PatientsCompletedNCT03366272Phase 2/3
- A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin LymphomaCompletedNCT03357627Phase 1
- Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin LymphomaStatus unknownNCT03355859Phase 1
- Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin LymphomaStatus unknownNCT03344367Phase 1
- B001 in Patients With CD20 Positive B-cell Non Hodgkin's LymphomaCompletedNCT03332121Phase 1
- A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesCompletedNCT03329950Phase 1
- Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell TransplantActive, not recruitingNCT03301168Phase 1/2
- A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHLStatus unknownNCT03299738Phase 1
- A Study of PLX2853 in Advanced Malignancies.CompletedNCT03297424Phase 1
- An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)CompletedNCT03289182
- Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHLActive, not recruitingNCT03283137Phase 1
- Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological MalignanciesCompletedNCT03263637Phase 1
- Dietary Milled Seed Mix in Patients With Non-Hodgkin LymphomaStatus unknownNCT03260231Not applicable
- Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 StudyStatus unknownNCT03260101
- Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHLStatus unknownNCT03245905Phase 2
- Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood TransplantationStatus unknownNCT03244930Phase 2
- Safety and Efficacy Evaluation of CD19-UCARTSuspendedNCT03229876Not applicable
- Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.Active, not recruitingNCT03229200Phase 4
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's LymphomasTerminatedNCT03220347Phase 1
- Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver DysfunctionWithdrawnNCT03217253Phase 1
- Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell LymphomasWithdrawnNCT03205891Phase 1
- Auto/Allo Tandem Transplant for Relapsed B-NHLCompletedNCT03205657
- CAR-T for R/R B-NHLCompletedNCT03196830Phase 2
- Diagnostic Assessment of 18F-fluciclovine and 18F-FDG -PET/MRI of Primary Central Nervous System LymphomaCompletedNCT03188354Not applicable
- Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22Status unknownNCT03185494Phase 1/2
- Micro Ribosomal Nucleic Acid 155 in Non Hodgkin LymphomaCompletedNCT03185325
- A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic LymphomaCompletedNCT03181126Phase 1
- QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHLWithdrawnNCT03169790Phase 1/2
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Active, not recruitingNCT03162536Phase 1/2
- Study of Safety and Efficacy of C-CAR011 in B-NHL PatientsStatus unknownNCT03154775Phase 1
- Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin LymphomaActive, not recruitingNCT03147885Phase 1/2
- Cyclophosphamide and Alemtuzumab In LymphomaTerminatedNCT03132584Phase 1
- Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)Status unknownNCT03105596Phase 2
- huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic LeukemiaTerminatedNCT03103971Phase 1
- Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20CompletedNCT03097770Phase 1/2
- Haploidentical Stem Cell Transplantation Using Post-Transplant CyclophosphamideTerminatedNCT03088709Phase 2
- A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's LymphomaActive, not recruitingNCT03075696Phase 1/2
- Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's LymphomaTerminatedNCT03074825Phase 1
- Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on LenalidomideTerminatedNCT03065790
- Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AuriхimCompletedNCT03057418Phase 1
- Using Telephone Counselling to Improve Exercise Participation in Hematologic Cancer SurvivorsCompletedNCT03052777Not applicable
- Autologous Transplant Using Dose-Escalated Total Body Irradiation & Cyclophosphamide & Palifermin for NHLCompletedNCT03042585Not applicable
- Prospective Comparison Between FDG-PET/MR and FDG-PET/CT in Classical Hodgkin Lymphoma and DLBC Non-Hodgkin LymphomaStatus unknownNCT03042247
- Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)CompletedNCT03039114Phase 1
- Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHLCompletedNCT03019666Phase 1
- A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)CompletedNCT03013218Phase 1
- Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 TrialCompletedNCT03003546Phase 1
- A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's LymphomaCompletedNCT03003039Phase 1
- The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of LymphomasStatus unknownNCT03000738
- HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday LifeStatus unknownNCT03000192
- Haploidentical BMT With Post-Transplant Cyclophosphamide and BendamustineCompletedNCT02996773Phase 1
- PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent NeutropeniaStatus unknownNCT02996617Phase 4
- Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCTCompletedNCT02992223
- Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell LymphomaStatus unknownNCT02987244Phase 1/2
- Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisPTerminatedNCT02983097Phase 1/2
- Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaStatus unknownNCT02981745Phase 1/2
- A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or LymphomaTerminatedNCT02978235Phase 1
- Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)CompletedNCT02973113Phase 1
- A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCLActive, not recruitingNCT02972840Phase 3
- A Phase II Study of the FIL on Elderly Frail Patients With DLBCLCompletedNCT02955823Phase 2
- Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromActive, not recruitingNCT02952508Phase 2
- Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT02950220Phase 1
- Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic LymphomaTerminatedNCT02928510
- Italian Multicenter Retrospective Observational Study on Transformed LymphomasStatus unknownNCT02927756
- A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's LymphomaTerminatedNCT02914938Phase 1
- A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical StudyCompletedNCT02875548Phase 1/2
- Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell TransplantActive, not recruitingNCT02861417Phase 2
- A Study of Mitoxantrone Hydrochloride Liposome InfusionStatus unknownNCT02856685Phase 1/2
- BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's LymphomaStatus unknownNCT02836639Phase 2
- Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins LymphomaTerminatedNCT02793583Phase 2/3
- Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior TransplantationActive, not recruitingNCT02790515Phase 2
- Development of a Tissue-Based & Cell Free DNA Next-Generation Sequencing WorkflowStatus unknownNCT02788084
- An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)CompletedNCT02782845Phase 4
- Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin LymphomasWithdrawnNCT02762448
- Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT02750670Phase 2
- DS-3201b in Participants With LymphomasActive, not recruitingNCT02732275Phase 1
- Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell LymphomaWithdrawnNCT02729961Phase 1/2
- Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCTTerminatedNCT02728700Phase 1
- A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)CompletedNCT02723071Phase 1/2
- Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's LymphomaStatus unknownNCT02722733Phase 3
- Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma PatientsStatus unknownNCT02721407Phase 1
- A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin LymphomaTerminatedNCT02702141Phase 1
- Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's LymphomaCompletedNCT02697552Phase 1
- Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHLActive, not recruitingNCT02690545Phase 1/2
- Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/LymphomaStatus unknownNCT02685670Phase 1/2
- A Study of PLX51107 in Advanced MalignanciesTerminatedNCT02683395Phase 1
- Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN StudyActive, not recruitingNCT02678299Phase 1/2
- Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell TransplantWithdrawnNCT02662296Phase 2